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Abstract: Coxsackievirus A24 variant (CVA24v) is the primary causative agent of the highly conta-
gious eye infection designated acute hemorrhagic conjunctivitis (AHC). It is solely responsible for
two pandemics and several recurring outbreaks of the disease over the last decades, thus affecting
millions of individuals throughout the world. To date, no antiviral agents or vaccines are available
for combating this disease, and treatment is mainly supportive. CVA24v utilizes Neu5Ac-containing
glycans as attachment receptors facilitating entry into host cells. We have previously reported that
pentavalent Neu5Ac conjugates based on a glucose-scaffold inhibit CVA24v infection of human
corneal epithelial cells. In this study, we report on the design and synthesis of scaffold-replaced
pentavalent Neu5Ac conjugates and their effect on CVA24v cell transduction and the use of cryogenic
electron microscopy (cryo-EM) to study the binding of these multivalent conjugates to CVA24v. The
results presented here provide insights into the development of Neu5Ac-based inhibitors of CVA24v
and, most significantly, the first application of cryo-EM to study the binding of a multivalent ligand
to a lectin.
Keywords: sialic acid conjugates; antivirals; conjunctivitis; coxsackievirus A24v; 5-N-acetylneuraminic
acid; multivalency; cryo-EM
1. Introduction
Viral pandemics have over the course of human civilization, caused the suffering and
deaths of millions of human beings [1]. The severe consequences of viral outbreaks and
pandemics are currently on global display, with the ravaging covid-19 pandemic that have
crippled societies causing serious and, potentially, long-lasting socio-economic effects at
both a local level and on a global scale.
Coxsackievirus A24 variant (CVA24v), an antigenic variant of coxsackievirus A24
(CVA24), has over the last decades caused two pandemics and several recurring outbreaks
of the highly contagious eye infection acute hemorrhagic conjunctivitis (AHC) with >10 mil-
lion estimated cases of the disease [2,3]. AHC is characterized by an abrupt onset of ocular
pain, swelling of the eyelids, watering, a foreign body sensation, and extensive subconjunc-
tival hemorrhaging [4]. The infection is highly contagious with short incubation periods
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(24–48 h) that result in explosive outbreaks in communities, affecting up to 50% of the
population [3–5]. AHC generally resolves spontaneously within 1–2 weeks, and although
severe conditions are rare, the development of acute flaccid paralysis and even fatalities
have been reported [5,6]. Treatment of AHC is supportive as neither vaccines nor antivirals
are currently available to combat the infection.
To facilitate attachment and subsequent entry into cells, CVA24v engages glycan-
containing receptors that terminate in 5-N-acetyl-neuraminic acid (Neu5Ac) and the inter-
cellular adhesion molecule-1 (ICAM-1), with ICAM-1 serving as the primary receptor [7].
Binding to ICAM-1 is essential for productive replication of CVA24, including variant and
non-variant strains, as binding initiates uncoating by triggering destabilizing rearrange-
ments of the capsid proteins that eventually result in the formation of a capsid-mediated
pore through which the viral genome is released into the cytoplasm of cells [7]. However,
the virulence and pandemic potential of CVA24v seems to be linked to enhanced efficiency
in binding Neu5Ac, which favors a tropism switch towards the eye [7]. This adaptation
has further been suggested to promote CVA24v attachment to corneal and conjunctival
cells [8] and thereby, resulting in enhancing the transmission of viral progeny [7]. CVA24v
binds Neu5Ac glycans via binding sites located within viral protein 1 (VP1) that together
cluster around the five-fold symmetry axis of the virion, in essence, forming pentameric
Neu5Ac lectins [9].
Protein-carbohydrate interactions are of vital importance in a wide range of biological
processes in health and disease. Yet, only a few carbohydrate-based drugs have reached
the market. This may be due to challenges associated with overcoming the generally weak
affinities of protein–carbohydrate interactions and the poor pharmacological properties
of carbohydrates as a result of their high polarity and metabolic vulnerability [10]. In the
case of CVA24v and many other viruses that employ Neu5Ac for host cell attachment,
these issues can potentially be circumvented by design of multivalent ligands intended for
a topical administration as the primary sites of replication are linked to the eyes and airways.
Importantly, direct topical administration to the site of infection would circumvent the
challenges posed by oral administration and systemic distribution of a carbohydrate drug.
Indeed, the design of multivalent carbohydrate ligands is a proven strategy used to achieve
high avidity binding to lectins (carbohydrate-binding proteins) via several mechanisms,
including the chelate effect, subsite binding, steric stabilization, statistical rebinding, and
receptor clustering [11]. Further, multivalent ligands tailored to lectin valency and topology
have been demonstrated to result in rather exceptional enhancements in avidity [12,13].
Other promising approaches include repurposing existing topical eye medications to be
used as broad-spectrum antivirals [14].
Bioisosteric replacements are broadly defined as the replacement of, e.g., functional
groups or a scaffold part of a bioactive molecule with a substructure that is similar in size
and properties. The strategy is widely used in compound optimization with the aim of
improving target binding, drug-like properties, reduce metabolic vulnerability, or reduce
toxicity. Replacement of the central scaffold of an active molecule with another scaffold
has in recent years gained increased attention [15]. This is the result of, e.g., development
of computational methods referred to as “scaffold hopping” [16] and the realization that
the diversity of scaffolds in approved drugs are relatively low [17]. Whether the selection
of a novel scaffold for an active compound is based on “scaffold hopping” methodology or
on traditional structure-based reasoning [18], the general idea is to retain enough similarity
for the compound to remain active, normally achieved by keeping key substituents for
binding. This may result in altering the properties of the molecule or may move it into
novel chemical space [15,16]. Scaffold-replacement has been demonstrated to result in
improved binding affinity [19] and cell permeability [20], and reduced toxicity [21]. Further,
decreased flexibility of the scaffold can increase the binding affinity of a molecule as the
loss of conformational entropy is reduced upon binding of the ligand to its target [22].
To date, pentavalent Neu5Ac conjugates based on a glucose scaffold are the most
efficient reported inhibitors of CVA24v attachment and infection of human corneal epithe-
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lial (HCE) cells [23]. Herein, we report on the synthesis of scaffold-replaced pentavalent
Neu5Ac conjugates and, to the best of our knowledge, the first use of cryogenic elec-




A total of 60 Neu5Ac binding sites decorate the CVA24v capsid. These are arranged
into 12 relatively flat, local five-fold symmetries, each providing five shallow, surface
exposed Neu5Ac binding sites [9]. We previously reported on the design and synthesis
of pentavalent Neu5Ac conjugates with pseudoradial topology that inhibit CVA24v at-
tachment to, and infection of, HCE cells [23]. These inhibitors were designed to chelate
each of the pentameric lectins of CVA24v. Crystal structures of inhibitor-bound CVA24v
confirmed compound binding, with observed electron density for the Neu5Ac units. How-
ever, negative-staining electron microscopy suggested that the major mode of binding
and inhibition of these inhibitors likely resulted from cross-linking and aggregation of
virus particles [23]. Thus, in order to further explore, and achieve, tailored chelation of the
Neu5Ac binding sites, a modification of the strategy was needed.
We reasoned that replacement of the glucose scaffold of the pentavalent Neu5Ac
conjugates potentially could result in direct contacts between the scaffold and the viral
capsid and thus result in improved efficacy. We hypothesized that tailored pentavalent
Neu5Ac conjugates with symmetric topology may facilitate detection of the remaining
parts of the inhibitors as the number of unique binding modes are significantly reduced,
and could thus result in more ordered binding events to the viral capsid. Theoretically, this
should result in higher avidity binding due to reduced loss of entropy in the inhibitor-lectin
interaction [24–26]. Further, although many different multivalent scaffold architectures
have been developed, the effect of scaffold-replacements in the optimization of multivalent
ligand structures is a rather underexplored topic as most reports have focused on ligand
valency and density and on the refinement of spacer length and characteristics [24].
Penta-butynyl-corannulene [27] was selected as the scaffold based on its five-fold
symmetry, equivalent to that of CVA24v, and due to the synthetic ease of accessing C5-
symmetric pentavalent Neu5Ac conjugates via the copper-catalyzed azide-alkyne cycload-
ditions (CuAAC). The scaffold may interact with amino acid residues of the capsid via
CH-π, cation-π, or π-π interactions [28,29]. In addition, the aromatic bowl-shaped backbone
of the corannulene scaffold imparts a dipole moment, through which interactions could
be induced [28]. Furthermore, bowl-inversions of the scaffold occur readily [30,31], thus,
either the concave or convex face of the scaffold can interact with the virus particle, which
may be ideal due to the spherical form of CVA24v.
Quantum mechanical molecular modeling was used to probe potential interactions
between the corannulene-scaffold and CVA24v. To reduce the computational demands of
the quantum mechanical calculations, a penta-propyl substituted corannulene molecule
was docked to a truncated region, consisting of 340 atoms, of one pentagon of CVA24v that
included the five-fold symmetry axis of the virion (Figure 1A).
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Figure 1. Energy minimization and modelling of scaffold and a pentavalent Neu5Ac conjugates to CVA24v. (A) penta-
propyl-corannulene and CVA24v atoms were included in the docking. (B) Energy minimized structure of the penta-pro-
pyl-corannulene. (C) Quantum mechanical molecular modeling of penta-propyl-corannulene scaffold to a truncated part 
of the “lectin receptor” of CVA24v. (D) Molecular mechanical modeling of a scaffold replaced corannulene-based penta-
valent Neu5Ac conjugate to CVA24v. 
The docking started with a low-energy penta-propyl-substituted corannulene (Fig-
ure 1B) that was manually placed on top of the five-fold center of CVA24v. Subsequently, 
the complex was geometry optimized in Jaguar [32] using density functional theory 
(BLYP-D3 [33], 6-31G **), with the molecule allowed to move freely over the viral surface 
with fixed atomic positions. The optimization converged after 48 cycles according to the 
direct inversion of the iterative space method [34]. No atomic clashes were identified, and 
beneficial arene interactions were present between histidine side chains and the corannu-
lene molecule (Figure 1C). This docked structure was then used to study the length of the 
spacers required for chelation of the pentameric lectins (Figure 1D) [23]. The docked struc-
ture of corannulene was connected to the sialic acids (X-ray coordinates), and the spacers 
were energy minimized. Spacers of increasing length were evaluated to minimize the 
strain where n = 1 led to a strained spacer and n = 5 was sufficiently long to avoid strain. 
2.2. Synthesis of Scaffold-Replaced Pentavalent Neu5Ac Conjugates 
Synthesis of the symmetric pentavalent Neu5Ac conjugates 12–14 was achieved in 
five steps from Neu5Ac donor 1 that was prepared from Neu5Ac as previously described 
(Scheme 1) [35]. 
Figure 1. Energy minimization and modelling of scaffold and a pentavalent Neu5Ac conjugates to CVA24v. (A) penta-
propyl-corannulene and CVA24v atoms were included in the docking. (B) Energy minimized structure of the penta-propyl-
corannulene. (C) Quantum mechanical molecular modeling of penta-propyl-corannulene scaffold to a truncated part of the
“lectin receptor” of CVA24v. (D) Molecular mechanical modeling of a scaffold replaced corannulene-based pentavalent
Neu5Ac conjugate to CVA24v.
The docking started with a low-energy penta-propyl-substituted corannulene
(Figure 1B) that was manually placed on top of the five-fold center of CVA24v. Subse-
quently, the complex was geometry optimized in Jaguar [32] using density functional
theory (BLYP-D3 [33], 6-31G **), with the molecule allowed to move freely over the viral
surface with fixed atomic positions. The optimization converged after 48 cycles according
to the direct inversion of the iterative space method [34]. No atomic clashes were identified,
and beneficial arene interactions were present between histidine side chains and the coran-
nulene molecule (Figure 1C). This docked structure was then used to study the length of
the spacers required for chelation of the pentameric lectins (Figure 1D) [23]. The docked
structure of corannulene was connected to the sialic acids (X-ray coordinates), and the
spacers were energy minimized. Spacers of increasing length were evaluated to minimize
the strain where n = 1 led to a strained spacer and n = 5 was sufficiently long to avoid strain.
2.2. Synthesis of Scaffold-Replaced Pentavalent Neu5Ac Conjugates
Synthesis of the sy etric pentavalent Neu5Ac conjugates 12–14 was achieved in
five steps fro eu5Ac donor 1 that as prepared fro eu5Ac as previously described
(Sche e 1) [35].
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Scheme 1. Synthesis of pentavalent corannulene-based Neu5Ac compounds. Reagents and conditions: (a) i: molecular 
sieves (3 Å), 2−4, CH3CN/CH2Cl2 (2:1), rt, 30 min, ii: silver trifluoromethane-sulfonate, IBr, −74 °C, 5.5 h. (b) NaN3, DMF, 
(c) Sodium methoxide, methanol, rt, 3 h, ii: H+ ion exchange resin. (d) CuSO4·5H2O, sodium ascorbate, tetrahydrofu-
ran/H2O (1:1), 8, 50 °C, 5 h → rt, 18 h. (e) i: LiOH, methanol, rt, 24 h, ii: H+ ion exchange resin. 
The sym-penta-(1-butyn-4-yl)-corannulene core 8 [27] was obtained in three steps 
from corannulene under standard conditions [27,31]. Neu5Ac donor 1 was sialidated us-
ing the glycosyl acceptors 2–4, respectively, under the promotion of silver trifluoro-
methanesulfonate and iodine monobromide [36], affording the corresponding bromo ac-
etyl protected sialosides. Subsequent treatment with sodium azide in dimethylformamide 
(DMF), followed by O-deacetylation afforded the known α-anomerically pure azido sialo-
sides 5 [13] and 6 [23], in 46% and in 70% yields, respectively, while 7 was isolated in 31% 
yield over the three steps. The azido sialosides 5–7 were then conjugated to the pentapro-
pargylated core 8 by the copper-catalyzed azide-alkyne cycloaddition affording the pen-
tavalent Neu5Ac methyl esters 9–11 in 25–62% yields. Treatment with lithium hydroxide 
in methanol and water liberated the corresponding pentavalent Neu5Ac compounds 12–
14 in quantitative yields after neutralization. 
2.3. Corannulene-Based Pentavalent Neu5Ac Conjugates Attenuate CVA24v Transduction 
To evaluate the biological effect of the scaffold-replaced Neu5Ac conjugates 12–14, 
the transduction of CVA24v at 37 °C was measured in HCE cells (Figure 2A), as previously 
described [23]. Ocular inspection of the cells by microscopy and cell counting (Figure S1) 
indicated that the compounds are non-toxic. 
Scheme 1. Synthesis of pentavalent corannulene-based Neu5Ac compounds. Reagents and conditions: (a) i: molec-
ular sieves (3 Å), 2−4, CH3CN/CH2Cl2 (2:1), rt, 30 min, ii: silver trifluoromethane-sulfonate, IBr, −74 ◦C, 5.5 h.
(b) NaN3, DMF, (c) Sodium methoxide, methanol, rt, 3 h, ii: H+ ion exchange resin. (d) CuSO4·5H2O, sodium ascor-
bate, tetrahydrofuran/H2O (1:1), 8, 50 ◦C, 5 h→ rt, 18 h. (e) i: LiOH, methanol, rt, 24 h, ii: H+ ion exchange resin.
The sym-penta-(1-butyn-4-yl)-corannulene core 8 [27] was obtained in three steps
from corannulene under standard conditions [27,31]. Neu5Ac donor 1 was sialidated using
the glycosyl acceptors 2–4, respectively, under the promotion of silver trifluoromethanesul-
fonate and iodine monobromide [36], affording the corresponding bromo acetyl protected
sialosides. Subsequent treatment with sodium azide in dimethylformamide (DMF), fol-
lowed by O-deacetylation afforded the known α-anomerically pure azido sialosides 5 [13]
and 6 [23], in 46% and in 70% yields, respectively, while 7 was isolated in 31% yield over the
three steps. The azido sialosides 5–7 were then conjugated to the pentapropargylated core
8 by the copper-catalyzed azide-alkyne cycloaddition affording the pentavalent Neu5Ac
methyl esters 9–11 in 25–62% yields. Treatment with lithium hydroxide in methanol and
water liberated the corresponding pentavalent Neu5Ac compounds 12–14 in quantitative
yields after neutralization.
2.3. Corannulene-Based Pentavalent Neu5Ac Conjugates Attenuate CVA24v Transduction
To evaluat the biological effect of the scaffold-replaced Neu5Ac conjugates 12–14, the
transduction of CVA24v at 37 ◦C was measured in HCE cells (Figure 2A), as previously
described [23]. Ocular inspection of the cells by microscopy and cell countin (Figure S1)
indicated at the c mpounds are n n-toxic.
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Figure 2. Effect of scaffold replacement on CVA24v transduction in HCE cells. (A) Effect of scaffold-replaced pentavalent 
Neu5Ac conjugates 12–14 on CVA24v transduction in HCE cells at 37 °C. Error bars are shown as the standard error of 
the mean (SEM). Data are presented as the % of control, that is, the value obtained in the absence of an inhibitor. All 
experiments were performed in duplicate and for a minimum of two times. (B) Structure of glucose-based pentavalent 
Neu5Ac conjugates ME0752. 
Compared with untreated virions, the transduction of CVA24v was significantly at-
tenuated when preincubated with 12–14. All inhibitors were significantly more potent 
than Neu5Ac [23] and disialyllacto-N-tetraose [9]. Control compound ME0752 with a β-
glucose scaffold (Figure 1B, compound 28 in reference [23]), attenuated transduction with 
>95% and 50% at 1.25 mM and 312.5 μM, respectively, but had no effect at lower concen-
trations. Compound 14, with the longest spacers, was the most efficient of the scaffold-
replaced compounds and reduced transduction by 80–85% and 25% at 1.25 mM and 312.5 
μM, respectively. Compounds 13 and 12, containing successively shorter spacers, reduced 
transduction by 75% and 60%, respectively, but had no effect at 312.5 μM. A plausible 
explanation for this could be that the spacers of compounds 12 and 13 are not of sufficient 
length to allow simultaneous binding of the Neu5Ac units of the compounds to the pen-
tameric lectins of CVA24v. It is also possible that the compounds cause cross-linking and 
aggregation as previously observed for glucose-based pentameric sialic acids, including 
ME0752 [23]. Nevertheless, the displayed inhibitory activity of compound 14 indicates 
that the glucose scaffold can be replaced with a corannulene scaffold, although for this 
particular system and set of compounds, it did not result in enhancing potency. 
2.4. X-ray Crystallography Supports Binding of Inhibitors to CVA24v 
The binding mode of 14 was structurally characterized by X-ray crystallography. The 
X-ray structure of 14-CVA24v was established to a resolution of 1.78 Å. Similar to the 
CVA24v structures with the glucose-based Neu5Ac inhibitors [23] (pdb code 6TSD), the 
14-CVA24v structure showed clear electron density for the Neu5Ac units in all five bind-
ing sites, each located within viral protein 1 (VP1). The electron density of the spacer 
points outward to the solvent and shows that the spacer does not have specific contacts 
to the viral shell. This results in a high degree of flexibility in that region, resulting in a 
blurry map that does not allow the placement of more than the first three atoms of the 
spacers of compound 14. Thus, the remaining parts of 14 were not resolved, suggesting 
that it is either not ordered or that the inhibitor does not accommodate a single confor-
mation. Further, it is possible that 14 does not bind in a chelating fashion similar to the 
Figure 2. Effect of scaffold replacement on CVA24v transduction in HCE cells. (A) Effect of scaffold-replaced pentavalent
Neu5Ac conjugates 12–14 on CVA24v transduction in HCE cells at 37 ◦C. Error bars are shown as the standard error of
the mean (SEM). Data are presented as the % of control, that is, the value obtained in the absence of an inhibitor. All
experiments were performed in duplicate and for a minimum of two times. (B) Structure of glucose-based pentavalent
Neu5Ac conjugates ME0752.
Compared with untreated virions, the transduction of CVA24v was significantly atten-
uated when preincubated with 12–14. All inhibitors were significantly more potent than
Neu5Ac [23] and disialyllacto-N-tetraose [9]. Control compound ME0752 with a β-glucose
scaffold (Figure 1B, compound 28 in reference [23]), attenuated transduction with >95%
and 50% at 1.25 mM and 312.5 µM, respectively, but had no effect at lower concentrations.
Compound 14, with the longest spacers, was the most efficient of the scaffold-replaced
compounds and reduced transduction by 80–85% and 25% at 1.25 mM and 312.5 µM,
respectively. Compounds 13 and 12, containing successively shorter spacers, reduced
transduction by 75% and 60%, respectively, but had no effect at 312.5 µM. A plausible
explanation for this could be that the spacers of compounds 12 and 13 are not of sufficient
length to allow simultaneous binding of the Neu5Ac units of the compounds to the pen-
tameric lectins of CVA24v. It is also possible that the compounds cause cross-linking and
aggregation as previously observed for glucose-based pentameric sialic acids, including
ME0752 [23]. Nevertheless, the displayed inhibitory activity of compound 14 indicates
that the glucose scaffold can be replaced with a corannulene scaffold, although for this
particular system and set of compounds, it did not result in enhancing potency.
2.4. X-ray Crystallography Sup orts Binding of Inhibitors to CVA24v
The binding mode of 14 was structurally characterized by X-ray crystallography. The
X-ray structure of 14-CVA24v was established to a resolution of 1.78 Å. Similar to the
CVA24v structures with the glucose-based Neu5Ac inhibitors [23] (pdb code 6TSD), the
14-CVA24v structure showed clear electron density for the Neu5Ac units in all five binding
sites, each located within viral protein 1 (VP1). The electron density of the spacer points
outward to the solvent and shows that the spacer does not have specific contacts to the
viral shell. This results in a high degree of flexibility in that region, resulting in a blurry
map that does not allow the placement of more than the first three atoms of the spacers of
compound 14. Thus, the remaining parts of 14 were not resolved, suggesting that it is either
not ordered or that the inhibitor does not accommodate a single conformation. Further,
it is possible that 14 does not bind in a chelating fashion similar to the glucose-based
pentavalent Neu5Ac conjugates that were observed to cross-link and aggregate CVA24v
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particles [23]. Thus, 14 may bind to Neu5Ac binding sites of separate CVA24v particles
within the crystal lattice, resulting in the absence of observed density as the spacers likely
adopt random orientations in the solvent. The interactions in the lectin binding sites of
CVA24v with the Neu5Ac units of compound 14 were similar as previously described [23]
(Figure 3), with the main exception that the C8 hydroxyl rather than the C9 hydroxyl of
Neu5Ac engages in intramolecular hydrogen bonding with the C2 carboxylate.
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as shown by an unbiased simulated annealing (Fo-Fc)-map (light orange) depicted at a contour level 
of 2.5 σ. The spacer to the corannulene core is flexible, resulting in a fuzzy electron density. There-
fore, neither the corannulene nor most parts of the spacer can be modeled into the crystal structure. 
2.5. Cryo-EM Supports Inhibitor Binding over the Five-Fold Axis of CVA24v 
To understand how compound 14 binds to CVA24v in solution, cryo-EM analysis 
was performed. To exclude the possibility of cross-linkage between the inhibitor and bind-
ing sites of neighboring capsids, we employed an on-grid binding strategy described pre-
viously [37,38]. This approach allowed us to determine the 14-CVA24v structure at an 
overall resolution of 2.3 Å (Figure 4A). 
Figure 3. Binding of compound 14 to CVA24v. Interactions of the Neu5Ac moiety of compound 14 to
amino acids in the ligand binding sites of CVA24v. The binding site located at the interface of two
lectins proteins (light blue, light grey) is occupied by the sialic acid entity (orange) of the inhibitor as
shown by an unbiased simulated annealing (Fo-Fc)-map (light orange) depicted at a contour level of
2.5 σ. The spacer to the corannulene core is flexible, resulting in a fuzzy electron density. Therefore,
neither the corannulene nor most parts of the spacer can be modeled into the crystal structure.
2.5 Cryo-EM Supports Inhibitor Binding over the Five-Fold Axis of CVA24v
To understand how compound 14 binds to CVA24v in solution, cryo-EM analysis
was performed. To exclude the possibility of cross-linkage between the inhibitor and
binding sites of neighboring capsids, we employed an on-grid binding strategy described
previously [37,38]. This approach allowed us to determine the 14-CVA24v structure at
an overall resolution of 2.3 Å (Figure 4A).
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i r . ryo-E analysis of CVA24v in complex with comp und 14. (A) Unsharpened cryo-EM reconstru tion of CVA24v
in complex with compound 14, viewed down the icosahedral two-fold axis. The capsid is colored according to the radial
coloring scheme, shown in angstroms, and the density corresponding to compound 14, visible at the five-fold symmetry
axis, is colored magenta. (B) Enlarged view of a single capsid five-fold from the sharpened cryo-EM map, showing clear
density for the sialic acid component of compound 14. (C) Zoomed in view of a single sialic acid binding site shown in (B).
(D) 3D classes obtained from no-alignments, focused classification of the five-fold symmetry axis, colored as in (A).
In the unsharpened map, which retains lower resolution features, a clear mushroom-
shaped density for compound 14 was visible at the capsid vertices (Figure 4A). However,
upon map sharpening, only the sialic acid component of the inhibitor was resolved at
high resolution, with a binding mode virtually identical to that observed in the X-ray
crystallography structure (Figures 3 and 4B,C). Because the core and spacer regions of
compound 14 were poorly resolved, focused classification [39] was performed on a single
five-fold symmetry axis of the CVA24v capsid to study alternative conformations of the
inhibitor. In this approach, 60 symmetrically redundant orientations were assigned to each
particle, and a mask was used to focus classification on a substructure within the virion.
In the absence of symmetry averaging, this approach revealed a striking heterogeneity in
the binding mode of compound 14 and demonstrated that the inhibitor density deviates
from five-fold symmetry (Figure 4D and Video S1). Moreover, in several classes, compound
14 is only localized to a subset of available sialic acid binding sites. This suggests that only
a couple of Neu5Ac appendages of the compound are in contact with the capsid at any
one time, and the others adopt random orientations in the solvent. Clearly, this indicates
that 14 is not capable of fully chelating the Neu5Ac binding sites of the CVA24v lectins.
Thus, it is plausible that a radial presentation of Neu5Ac ligands is not an appropriate
design strategy for this particular system, possibly due to the overall topology of the
lectin-receptor. The rising of the protein surface from the center of the five-fold symmetry
axis of t e virion in relati n to the Neu5Ac binding sites gives the lectin-receptor an
overall convex-concave-convex surface going from one Neu5Ac binding site across the
c nter to another. Computational work studying the stability of complex s between
divalent ligands and bivalent receptors with concave (i.e., depression or channel) or convex
(i.e., rising o hill) surfaces between the binding sites, have shown that spacer-recept
interactions ar particularly detrimental in convex receptors and result in va ishing avidity
enhancements [40]. I is possible that similar factors play a role in th s particular system
as well.
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3. Conclusions
In this study, we performed structure-based scaffold hopping on pentavalent Neu5Ac
conjugates in an attempt to achieve a chelating binding to CVA24v, and evaluated the
effect of the scaffold replaced compounds on CVA24v transduction. The rationale for the
replacement of a glucose scaffold with corannulene was confirmed by quantum mechanical
docking of the corannulene scaffold to CVA24v that indicated the presence of beneficial
arene interactions to the protein surface of CVA24v. The effect of the scaffold-replaced
pentavalent Neu5Ac compounds generated no beneficial effect on the inhibition of CVA24v
transduction in relation to the glucose-based inhibitor ME0752. We used cryo-EM to
study the binding of the corannulene-based compound 14 to CVA24v, which indicated
that binding does not occur via the intended chelation of the binding sites. Thus, we find
it reasonable to speculate that this is a major contributing factor to the small observed
avidity gains achieved by both the glucose- and corannulene-based pentavalent Neu5Ac
conjugates. Likely, a mixture of multivalent binding mechanisms are operating at any
given time resulting in the inhibition of CVA24v transduction. This is valuable information
for the future development of Neu5Ac-based inhibitors of CVA24v. Future studies could
explore the effect of multivalent Neu5Ac conjugates with different topologies.
4. Materials and Methods
4.1. Computational Modelling
The molecular structure of the penta-propyl-corannulene was energy minimized
using the semi-empirical method Austin model 1 (AM1) [41,42] followed by geometry
optimization with density functional theory (DFT) in Jaguar (Schrödinger, New York, NY,
USA) [32,43] using functional B3LYP [33,43,44] and basis set CC-PVTZ. This resulted in
a low-energy structure with the expected bowl-shaped corannulene moiety (Figure 1A).
The docking of penta-propyl-corannulene to a truncated region of CVA24v, consisting of
340 atoms of 1 pentagon, started with the manual placement followed by a optimization
of the interaction using DFT (BLYP-D3 [33,44,45], 6-31G **) in Jaguar [32,43]. During the
geometry optimization, the penta-propyl-corannulene was allowed to move but the virus
binding site, including protein atom in close proximity (Figure 1A), had fixed atomic
positions. The optimization converged after 48 cycles according to the direct inversion
of the iterative subspace method [34]. No atomic clashes were identified, and there was
an indication for a beneficial arene interaction between corannulene and the proximal
histidine side chains in the binding site (Figure 1B). Using this docked structure, spacers of
different lengths to the sialic acid moiety were hypothesized and tested.
4.2. CVA24v Production and CVA24v Transduction
CVA24v of high purity (Figure S2) was produced as described previously [8,9] and
the CVA24v transduction assay was carried out according to established protocols [23].
4.3. Crystallization and Structure Determination
CVA24v was crystallized and derivatized as previously reported [9]. Briefly, com-
pound 14 (17 mM) was soaked overnight at 4 ◦C before the crystals were harvested and
flash-frozen in liquid nitrogen. Data were collected at beamline I03 at Diamond Light
Source, Oxford, United Kingdom (UK). Data reduction was performed using XDS [46],
followed by molecular replacement using rigid body refinement as implemented in REF-
MAC5 [47]. Simulated annealing using Phenix [48] was applied to remove model bias.
The final model resulted from cyclic real-space refinement using COOT [49] and reciprocal
space refinement as implemented in REFMAC5. Strict NCS parameterization was applied
in all later refinement steps (Table 1). The structure was validated using MOLPROBITY [50]
before structure factor amplitudes and coordinates were deposited to the protein data bank
(pdb entry 7OJ7). Figures were generated using PYMOL [51].
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Table 1. Data collection and refinements statistics for CVA24v in complex with 14. Values in
parentheses are for the highest resolution shell.
CVA24v:14 Complex
Resolution (Å) 50 50–1.78 (1.89–1.78)
Space group I222
Unit cell
a, b, c (Å) 305.13, 365.55, 366.71
No of reflections 14,772,705 (2,349,016)
unique reflections 1,921,680 (308,924)
Redundancy 7.7 (7.6)
Completeness (%) 99.9 (99.7)
I/σ (I) 6.6 (1.1)
CC1/2 98.6 (50.6)
Wilson B (Å2) 21.9
Rmeas (%) 28.2 (142.8)
Rwork (%) 15.8
Rmsd
Bond angle (◦) 1.36









Cryo-EM grids were prepared by applying 3 µL of purified CV-A24v (9.6 mg/mL) to
400 mesh lacey grids coated in a 3 nm carbon film (Agar Scientific, Essex, UK). The sample
was left to adsorb for 30 s, and then the excess sample was removed by manual blotting.
On-grid binding of pentavalent Neu5Ac conjugate was then performed by applying 3 µL
of a 5 mM solution of compound 14 in PBS to the pre-blotted, CV-A24v-coated grid, and
leaving for 30 s before blotting and freezing using a Leica EM GP plunge freeze device
(Leica Microsystems, Wetzlar, Germany). The Leica EM chamber temperature was set to
8 ◦C with 80% relative humidity and liquid ethane was used for sample vitrification. Grids
were glow discharged at 20 mA for 30 s prior to application of the sample, using a PELCO
easiGlow™ (Ted Pella, Redding, CA, USA). All data sets were collected on a Titan Krios
(Thermo Fisher Scientific, Waltham, MA, USA) transmission electron microscope operating
at 300 kV, at a nominal magnification of 165,000×. A total of 1443 exposures were recorded
using EPU automated acquisition software on a Gatan K2 summit camera operating in
super-resolution mode, using a total electron dose of 48.9 e−/Å2. Each movie had a total
exposure of 10 s and contained 50 fractions. The final calibrated physical pixel size was
0.82 Å. Detailed information on data collection was shown in Table 2.




Detector (mode) K2 super resolution
Accelerating voltage (ke−V) 300
Pixel size (Å) 0.82
Data acquisition parameters
Nominal magnification 165 k
Spot size 7
Illuminated area 1.31




Square pixel (Å2) 0.67
Dose per physical pixel per second 3.28
Dose per Å2/s 4.89
Exposure time (seconds) 10
Total dose (e/Å2) 48.9
Number of fractions 50
Dose per fraction (e/Å2) 0.97
EPU parameters
Defocus range (−µm) −0.5 to −2.3 (0.2 increments)
Autofocus After distance, 10 µm
Drift measurement Each grid square, 0.05 nm/s
Delay after stage shift 10 s
Delay after image shift na
Exposures per hole na







Initial particle images (No.) 23,952
Final particle images (No.) 8865
Map resolution (Å) 2.3
FSC threshold 0.143
Map sharpening B-factor (Å2) −49
Symmetry imposed I1
Image Processing
Following cryo-EM data collection, the RELION-3.0 pipeline [52] as used for image
processing. Drift correction was first performed on micrograph stacks using MOTION-
COR2 [53], and the contrast transfer function for each was estimated using Gctf [54].
A subset of virus particles was picked manually and subjected to 2D classification, with
the resultant classes used as templates for automatic particle picking [55]. Particles were
classified through multiple rounds of reference-free 2D classification, and particles in poor
quality classes were removed after each round. Using the ‘molmap’ command in UCSF
chimera [56], the CV-A24v crystal structure (PDB ID: 4Q4V [9]) was used to generate a 40 Å
resolution starting model to use as a reference for 3D autorefinement, with icosahedral
symmetry imposed. This reconstruction was postprocessed to mask and correct for the
B-factor of the map before taking particles forward to contrast transfer function (CTF)
refinement and Bayesian polishing [57]. The final reconstruction at 2.3 Å was computed
after correcting for the curvature of the Ewald sphere [52]. The nominal resolution the
map was determined according to the ‘gold standard’ Fourier shell correlation (FSC) cri-
terion (FSC = 0.143) [55] and a negative B-factor of −49 Å2 was applied during the final
post-processing step. The local resolution estimation tool in RELION was used to generate
a map filtered by local resolution.
To investigate the conformational heterogeneity of compound 14, a focused 3D classi-
fication approach was employed (as described previously [39]). Briefly, each particle con-
tributing to the final icosahedral-symmetry–imposed reconstruction was assigned 60 orien-
tations corresponding to its icosahedrally related views using the relion_symmetry_expand
tool. SPIDER [58] was used to generate a spherical mask, which was manually placed
over the map to isolate the fivefold symmetry axis of the capsid, and the symmetry-
expanded particles were subjected to masked 3D classification without alignment using
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a regularization parameter (‘T’ number) of 20. During the no-alignments 3D classification,
the resolution in the E-step was limited to 12 Å. Figures were generated using UCSF
Chimera [56] and UCSF ChimeraX [59].
4.5. General Chemical Procedures
1H NMR and 13C NMR spectra were recorded with a Bruker DRX-400 spectrometer
(Bruker, Billerica, Massachusetts, USA) at 400 MHz and 100 MHz, respectively, or with
a Bruker DRX-600 spectrometer at 600 MHz and 150 MHz, respectively. NMR experi-
ments were conducted at 298 K in D2O (residual solvent peak = 4.79 ppm (δH), CD3OD
(residual solvent peak = 3.31 ppm (δH) and 49.00 ppm (δC)), or CDCl3 (residual solvent
peak = 7.26 ppm (δH) and 77.16 ppm (δC)). Liquid chromatography mass spectrome-
try (LCMS) were recorded by detecting positive/negative ion (electrospray ionization,
ESI) on Agilent 1290 infinity II−6130 Quadrupole (Agilent, Santa Clara, CA, USA) using
H2O/CH3CN (0.1% formic acid) as the eluent system or on Agilent 1290 infinity−6150
Quadrupole using YMC Triart C18 1.9 µm, 20 × 50 mm column (Genetec, Nacka, Sweden)
and H2O/CH3CN (0.1% formic acid) as the eluent system. High resolution mass spectra
(HRMS) data were recorded with Agilent 1290 binary LC System connected to a Agilent
6230 Accurate-Mass Time-of-Flight (TOF) LC/MS (ESI+) (Agilent, Santa Clara, CA, USA);
calibrated with Agilent G1969-85001 ES-TOF Reference Mix containing ammonium tri-
fluoroacetate, purine and hexakis(1H, 1H, 3H tetrafluoropropoxy)phosphazine in 90:10
CH3CN/H2O. Semi-preparative HPLC separations were performed on a Gilson system
high performance liquid chromatography (HPLC), using a YMC-Actus Triart C18, 12 nm,
S-5 µm, 250 × 20 mm (Genetec, Nacka, Sweden) with a flow rate 20 mL min−1, detec-
tion at 214 nm and eluent system A: aqueous 0.005% formic acid, and B: CH3CN 0.005%
formic acid. Column chromatography was performed on silica gel (60 Å, 70–230 mesh
ASTM). Thin layer chromatography (TLC) were performed on Silica gel 60 F254 (Merck
KGaA, Darmstadt, Germany) with detection under UV light and/or development with
5% H2SO4 in EtOH and heat. Automated flash column chromatography was performed
using a Biotage Isolera One system (Biotage Sweden, Uppsala, Sweden) and purchased
pre-packed silica gel cartridges (Biotage SNAP Cartridge, KP-Sil). Freeze drying was per-
formed by freezing the diluted CH3CN/water solutions in dry ice-acetone bath and then
employing a Scanvac CoolSafe freeze dryer connected to an Edwards 28 rotary vane oil
pump (Labogene, Allerœd, Denmark). Organic solvents were dried using a Glass Contour
Solvent Systems (SG Water, NH, USA) except CH3CN (freshly distilled from CaH2) and
MeOH that were dried over molecular sieves 3 Å. Corannulene and 4-bromo-1-butanol
were purchased from abcr GmbH Germany (Karlsruhe, Germany), and all other chemicals
from Sigma-Aldrich. All chemicals and were used as received. All target compounds were
≥95% pure according to HPLC UV-traces. Statistics were calculated using GraphPad Prism
7 (GraphPad Software, La Jolla, CA, USA). Microwave reactions were performed using
a Biotage Initiator microwave synthesizer (Biotage Sweden, Uppsala, Sweden); tempera-
tures were monitored by an internal IR probe; stirring was mediated magnetically, and
the reaction was carried out in sealed vessels. Automated flash column chromatography
was performed using a Biotage® Isolera One system and purchased pre-packed silica gel
cartridges (Biotage SNAP Cartridge, KP-Sil, Biotage Sweden, Uppsala, Sweden).
4.5.1. General Procedure for Synthesis of Deprotected Azido-Sialosides
An oven-dried round bottom flask was charged with magnetic stirring bar, powdered
activated molecular sieves (4Å, 3.3 g), xanthate sialoside donor (1.0913 mmol, 1.0 eq) and
placed under N2 atmosphere. To this mixture was added CH2Cl2 (50 mL), bromoalcohol
(2, 3, or 4, respectively, 1.20 eq), and under dark conditions, a solution of silver trifluo-
rmethansulfonate (2.0 eq) in freshly distilled CH3CN (77 mL). The solution was cooled
to −72 ◦C and stirred for 15 min, followed by dropwise addition of a solution of IBr
(1.0 M in CH2Cl2, 1.40 eq). After complete addition of the IBr solution, the reaction was
stirred for 2 h at −72 ◦C, and N,N-diisopropylethylamine (DIPEA) (6.0 eq) was added
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and stirred for another 20 min at −72 ◦C, and another 20 min before warming to rt. The
mixture was filtered through a plug of celite and concentrated to dryness. The resulting
mixture was purified by flash chromatography (CH2Cl2/CH3OH gradients), affording the
protected sialosides as a mixture of alpha and beta anomers, in addition to the elimination
product. The mixture (544 mg, 0.8312 mmol) was subsequently dissolved in DMF (25 mL)
and treated with NaN3 (6.0 eq) followed by tetra-n-butylammonium iodide (2.0 eq). The
reaction was allowed to stir under nitrogen atmosphere for 22 h. The mixture was diluted
in CH2Cl2, washed with water, HCl (1 M), and brine. The organic layer was dried of
anhydrous Na2SO4, filtered and concentrated under reduced pressure affording crude
product, which was used without additional purification. The crude was dissolved in
a 0.03 M solution of sodium methoxide (a total of 10.0 equiv.). The reaction was allowed to
stir at rt under nitrogen atmosphere for 24 h. The solution was neutralized by the addition
of Dowex 50 × 8 H-form (pre-washed with MeOH), filtered, and concentrated to dryness.
Mixture was purified using column chromatography (CH2Cl2/MeOH, from 6% MeOH to
10% MeOH), affording the deprotected azido sialosides 5–7 as pure α-anomers. See below
for specific yields and analytical data.
4.5.2. General Procedure for CuAAC
An oven-dried round bottom flask equipped with magnetic stirring bar was charged
with azido-sialoside (0.37 mmol, 11.5 eq). To this was added a solution of pentapropar-
gylated corannulene core 8 (1.0 eq, 0.032 mmol) in tetrahydrofuran (THF, 7 mL). To the
stirring solution was added CuSO4.5H2O (1.59 eq) and sodium ascorbate (1.55 eq) in H2O
(7 mL). The flask was equipped with rubber septa and the mixture was heated to 50 ◦C for
5 h and then the reaction was left to perform at room temp for 36 h. The THF was removed
under reduced pressure, and the resulting mixture was injected on HPLC (MeCN/H2O
10%→ 25% gradient in 25 min), affording the pentavalent methyl ester derivative after
freeze-drying. See chemical synthesis for specific yields and analytical data.
4.5.3. General Procedure for Ester Hydrolysis
The pentavalent methyl ester derivate (0.01 mmol, 1.0 eq) was dissolved in CH3OH
(1.35 mL), and to this stirring solution was added a 1M solution of LiOH (0.156 mL,
15.0 eq). The mixture was stirred for 48 h at room temperature in the dark. The mixture
was neutralized (pH 7–8) with Dowex 50x8 H-form, filtered, and concentrated under
reduced pressure. The resulting residue was diluted in water and freeze-dried to afford the
pentavalent target compound.
Methyl (2-(6-azidohexoxy)(5-N-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonylopyranosyl))-onate (7). 1H NMR (600 MHz, CD3OD): δ 1.32–1.43 (m, 4H), 1.50–1.52
(m, 4H), 1.73 (dd, J = 12.8 Hz, 11.9 Hz, 1H), 2.00 (s, 3H), 2.68 (dd, J = 12.9 Hz, 4.7 Hz, 1H),
3.28 (appear as t, J = 6.9 Hz, 2H), 3.34–3.39 (m, 1H), 3.51 (dd, J = 8.9 Hz, 1.8 Hz, 1H), 3.55
(dd, J = 10.4 Hz, 1.8 Hz, 1H), 3.60–3.66 (m, 2H), 3.75 (t, J = 10.3 Hz, 1H), 3.79 (dd, J = 6.3 Hz,
3.0 Hz, 1H), 3.80–3.87 (m, 2H), 3.84 (s, 3H). 13C NMR (150 MHz, CD3OD): δ 22.65, 26.62,
27.48, 29.85, 30.55, 41.77, 52.41, 53.33, 53.87, 64.68, 65.03, 68.55, 70.20, 72.56, 74.93, 100.20,
171.23, 175.26. ESI-MS m/z calculated for C21H22O6 [M + Na]+ 393.1; found 393.1. HRMS
(ESI-TOF) m/z: [M + H]+ Calcd for C18H32N4O9 449.2242; Found 449.2255.
sym-Penta-2-[1-[2-((N-acetyl-1-methyl-α-neuraminosyl)oxy)ethyl]-1H-1,2,3-triazol-4-
yl]ethylcorannulene (9). 1H NMR (600 MHz, CD3OD): δ 1.68 (dd, J = 12.8 Hz, 11.6 Hz,
5H), 1.97 (s, 15H), 2.58 (dd, J = 12.7 Hz, 3.8 Hz, 5H), 3.07–3.27 (m, 10H), 3.44–3.53 (m, 15H),
3.55–3.68 (m, 15H), 3.60 (s, 15H), 3.73–3.87 (m, 20H), 4.10–4.18 (m, 5H), 4.45–4.53 (m, 10H),
7.63 (s, 5H), 7.79 (s, 5H). 13C NMR (150 MHz, CD3OD): δ 22.76, 29.15, 34.15, 41.42, 51.41,
53.47, 53.72, 63.89, 64.80, 68.33, 70.13, 72.26, 75.03, 100.24, 124.12, 124.70, 124.72, 130.81,
135.91, 141.29, 170.44, 175.13. HRMS (ESI-TOF) m/z: [M + 2H]+ Calcd. for C110H150N20O45
1236.5105; found 1236.5132.
sym-Penta-2-[1-[4-((N-acetyl-1-methyl-α-neuraminosyl)oxy)butyl]-1H-1,2,3-triazol-4-
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yl]ethylcorannulene (10). 1H NMR (600 MHz, CD3OD): δ 1.25–1.45 (m, 10H), 1.70 (dd,
J = 12.9 Hz, 11.0 Hz, 5H), 1.78–1.91 (m, 10H), 1.99 (s, 15H), 2.63 (dd, J = 12.9 Hz, 4.6 Hz, 5H),
3.22 (appear as t, J = 7.3 Hz, 10H), 3.27–333 (overlapped with solvent, 5H), 3.47 (appear
as t, J = 7.3 Hz, 10H), 3.51 (dd, J = 9.1 Hz, 0.9 Hz, 5H), 3.56 (dd, J = 10.4 Hz, 1.3 Hz, 5H),
3.60–3.67 (m, 10H), 3.67–3.79 (m, 10H), 3.75 (s, 15H), 3.80–3.85 (m, 10H), 4.25–4.38 (m,
10H), 7.60 (s, 5H), 7.67 (s, 5H). 13C NMR (150 MHz, CD3OD): δ 22.72, 27.83, 28.11, 29.12,
34.13, 41.67, 50.61, 53.45, 53.84, 64.32, 64.75, 68.49, 70.20, 72.49, 74.93, 100.14, 123.92, 124.33,
130.85, 135.86, 135.86, 141.30, 171.05, 175.21. HRMS (ESI-TOF) m/z: [M + 2H]+ Calcd. for
C120H170N20O45 1306.5887; found 1306.5891.
sym-Penta-2-[1-[6-((N-acetyl-1-methyl-α-neuraminosyl)oxy)hexyl]-1H-1,2,3-triazol-4-
yl]ethylcorannulene (11). 1H NMR (400 MHz, CD3OD): δ 1.09–1.20 (m, 10H), 1.21–1.32 (m,
10H), 1.33–1.43 (m, 10H), 1.66–1.80 (m, 15 H), 2.0 (s, 15H), 2.65 (dd, J = 12.8 Hz, 4.6 Hz, 5),
3.16–3.24 (m, 10H), 3.24–3.30 (m, 5H), 3.41–3.50 (m, 10H), 3.51 (dd, J = 8.6Hz, 1.8Hz, 5H),
3.54 (dd, J = 1.5 Hz, 1.6 Hz, 5H), 3.58–3.76 (m, 20H), 3.79 (s, 15H), 3.81–3.87 (m, 10H), 4.26
(t, J = 7.1 Hz, 10H), 7.58 (s, 5H), 7.65 (s, 5H). 13C NMR (150 MHz, CD3OD): δ 22.66, 26.60,
27.46, 29.83, 30.52, 41.75, 52.39, 53.35, 53.85, 64.66, 65.01, 68.52, 70.17, 72.54, 74.91, 100.17,
171.20, 175.24. HRMS (ESI-TOF) m/z: [M + 2H]+ Calcd. for C130H190N20O45 1376.6670;
found 1376.6679.
sym-Penta-2-[1-[2-((N-acetyl-α-neuraminosyl)oxy)ethyl]-1H-1,2,3-triazol-4-yl]ethyl
corannulene (12). 1H NMR (600 MHz, D2O): δ 1.49 (appear as t, J = 12.4 Hz, 5H), 1.99
(s, 15H), 2.58 (dd, J = 12.3 Hz, 4.8 Hz, 5H), 3.05–3.25 (m, 10H), 3.30–3.40 (overlapped
with solvent, 10H), 3.53 (dd, J = 8.7 Hz, 1.7 Hz, 5H), 3.55–3.65 (m, 15H), 3.67–3.63 (m,
10H), 3.74–3.78 (m, 5H), 3.80 (dd, J = 11.1 Hz, 2.6 Hz, 5H), 3.93–4.02 (m, 5H), 4.26–4.46 (m,
10H), 7.33 (s, 5H), 7.54 (s, 5H). 13C NMR (150 MHz, CD3OD): δ 50.19, 51.78, 62.50, 62.59,
68.08, 68.12, 71.57, 72.59, 100.45, 122.86, 124.11, 129.06, 133.42, 139.67, 147.20, 173.21, 174.92.
HRMS (ESI-TOF) m/z: [M + 2H]+ Calcd for C105H140N20O45 1201.4714; Found 1201.4736.
sym-Penta-2-[1-[4-((N-acetyl-α-neuraminosyl)oxy)butyl]-1H-1,2,3-triazol-4-yl]ethyl
corannulene (13). 1H NMR (600 MHz, CD3OD): δ 0.77–1.04 (m, 10H), 1.41–1.66 (m, 10H),
1.53 (appear as t, J = 12.2 Hz, 5H), 2.02 (s, 15H), 2.65 (dd, J = 12.3 Hz, 4.7 Hz, 5H), 3.09–3.29
(m, 15H), 3.29–3.48 (m, 15H), 3.53–3.68 (m, 20H), 3.68–3.87 (m, 5H), 3.73 (appear as t,
J = 10.1 Hz, 5H), 3.81 (dd, J = 11.8 Hz, 2.2 Hz, 5H), 3.98–4.29 (m, 10H), 7.29 (s, 5H), 7.41 (s,
5H). 13C NMR (150 MHz, CD3OD): δ 22.00, 25.31, 26.04, 27.12, 31.99, 40.26, 49.46, 51.90,
62.45, 63.35, 68.09, 68.28, 71.65, 72.53, 100.47, 123.29, 123.53, 129.43, 133.53, 139.80, 146.91,
173.47, 175.03. HRMS (ESI-TOF) m/z: [M + 2H]+ Calcd for C115H160N20O45 1271.5496;
found 1271,5494.
sym-Penta-2-[1-[6-((N-acetyl-1-methyl-α-neuraminosyl)oxy)hexyl]-1H-1,2,3-triazol-4-
yl]ethylcorannulene (14). 1H NMR (600 MHz, CD3OD): δ 0.53–0.72 (m, 10H), 0.84–0.98 (m,
10H), 1.03–1.16 (m, 10H), 1.29–1.45 (m, 10H), 1.57 (t, J = 12.1 Hz, 5H), 2.02 (s, 15H), 2.69 (dd,
J = 12.6 Hz, 4.7 Hz, 5H), 3.03–3.17 (m, 10H), 3.17–3.30 (m, 15H), 3.45–3.52 (m, 5H), 3.57 (dd,
J = 9.1 Hz, 1.9 Hz, 5H), 3.59–3.68 (m, 15H), 3.75 (appear as t, J = 10.1 Hz, 5H), 3.78–3.86 (m,
10H), 4.0–4.16 (m, 10H), 7.17 (s, 5H), 7.23 (s, 5H). 13C NMR (150 MHz, CD3OD): δ 22.03,
24.33, 24.93, 26.95, 28.62, 29.15, 31.83, 40.53, 49.78, 51.99, 62.48, 64.52, 68.16, 68.32, 71.74,
72.54, 100.59, 122.72, 123.29, 128.85, 133.17, 139.25, 146.83, 173.47, 175.04. HRMS (ESI-TOF)
m/z: [M + Na]+ Calcd for C125H180N20O45 1341.6279; found 1341.6302.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ijms22168418/s1.
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